Unaudited Standalone and Consolidated Financial Results of the company for the quarter ended 30th June 2025
3BBLACKBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
3B BlackBio Dx reported Q1 FY26 results with standalone revenue from operations of Rs 2,035.71 lakhs vs Rs 1,750.69 lakhs in Q1 FY25, a growth of about 16% year-on-year. Total income rose to Rs 2,467.13 lakhs from Rs 2,118.47 lakhs. Standalone profit after tax was Rs 1,246.04 lakhs vs Rs 1,073.29 lakhs (up ~16%), with EPS of Rs 14.54 vs Rs 12.53. On a consolidated basis, revenue from operations grew to Rs 2,223.46 lakhs from Rs 1,943.40 lakhs and PAT was Rs 1,264.45 lakhs vs Rs 1,129.76 lakhs. Other expenses included a one-time Rs 84.06 lakhs for M&A advisory and due diligence tied to the acquisition of Coris Bioconcept SRL, Belgium. The Diagnostic kits segment continues to dominate, contributing Rs 1,996 lakhs of segment revenue versus just Rs 227 lakhs from Agrochemicals. The Board also re-appointed Mr Dhirendra Dubey as Chairman and MD for 5 years and appointed Mr Vivek Saihgal as Independent Director.
Strong quarter with double-digit revenue and profit growth, driven by the Diagnostic kits business which is the core growth engine. The acquisition of Coris Bioconcept (Belgium) signals international expansion, but shareholders should watch integration costs and segment performance in coming quarters.